Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: Standardization of immune quality controls

Stem Cells and Development

Volumn 22, Issue 12, 2013, Pages 1789-1801

  Menard, Cedric ^a,b   Pacelli, Luciano ^c   Bassi, Giulio ^c   Dulong, Joelle ^a,b   Bifari, Francesco ^c   Bezier, Isabelle ^a,b   Zanoncello, Jasmina ^c   Ricciardi, Mario ^c   Latour, Maelle ^a   Bourin, Philippe ^d   Schrezenmeier, Hubert ^e   Sensebé, Luc ^d   Tarte, Karin ^a,b   Krampera, Mauro ^c  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b INSERM U917   (France)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE;

ADIPOSE TISSUE CELL; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CELL GROWTH; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; FETAL CALF SERUM; GOOD MANUFACTURING PRACTICE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; MESENCHYMAL STROMA CELL; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; STANDARDIZATION; T LYMPHOCYTE; THROMBOCYTE;

ADIPOSE TISSUE; ANIMALS; B-LYMPHOCYTES; BLOOD PLATELETS; BONE MARROW CELLS; CATTLE; CELL EXTRACTS; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; HUMANS; IMMUNOMODULATION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KILLER CELLS, NATURAL; MESENCHYMAL STROMAL CELLS; ORGAN SPECIFICITY; QUALITY CONTROL; SERUM; T-LYMPHOCYTES;

EID: 84877938781     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0594     Document Type: Article

References (62)

1. Uccelli A, L Moretta and V Pistoia. (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726-736.
2. Tan J, W Wu, X Xu, L Liao, F Zheng, S Messinger, X Sun, J Chen, S Yang, et al. (2012). Induction therapy with autolo-gous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307:1169-1177.
3. Connick P, M Kolappan, C Crawley, DJ Webber, R Patani, AW Michell, MQ Du, SL Luan, DR Altmann, et al. (2012). Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 11:150-156.
4. Ciccocioppo R, ME Bernardo, A Sgarella, R Maccario, MA Avanzini, C Ubezio, A Minelli, C Alvisi, A Vanoli, et al. (2011). Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 60:788-798.
5. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, E Lanino, B Sundberg, ME Bernardo, et al. (2008). Me-senchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579-1586.
6. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, D Prockop and E Horwitz. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315-317.
7. Sensebe L, P Bourin and K Tarte. (2011). Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther 22:19-26.
8. De Ugarte DA, Z Alfonso, PA Zuk, A Elbarbary, M Zhu, P Ashjian, P Benhaim, MH Hedrick and JK Fraser. (2003). Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett 89:267-270.
9. Pachon-Pena G, G Yu, A Tucker, X Wu, J Vendrell, BA Bunnell and JM Gimble. (2011). Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. J Cell Physiol 226:843-851.
10. Strioga M, S Viswanathan, A Darinskas, O Slaby and J Mi-chalek. (2012). Same or not the same? comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev 21:2724-2752.
11. Ivanova-Todorova E, I Bochev, M Mourdjeva, R Dimitrov, D Bukarev, S Kyurkchiev, P Tivchev, I Altunkova and DS Kyurkchiev. (2009). Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesen-chymal stem cells. Immunol Lett 126:37-42.
12. Bernardo ME, MA Avanzini, C Perotti, AM Cometa, A Moretta, E Lenta, C Del Fante, F Novara, A de Silvestri, et al. (2007). Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol 211:121-130.
13. Noel D, D Caton, S Roche, C Bony, S Lehmann, L Casteilla, C Jorgensen and B Cousin. (2008). Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res 314:1575-1584.
14. Tarte K, J Gaillard, JJ Lataillade, L Fouillard, M Becker, H Mossafa, A Tchirkov, H Rouard, C Henry, et al. (2010). Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 115:1549-1553.
15. Bocelli-Tyndall C, P Zajac, N Di Maggio, E Trella, F Ben-venuto, G Iezzi, A Scherberich, A Barbero, S Schaeren, et al. (2010). Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum 62:3815-3825.
16. Sotiropoulou PA, SA Perez, M Salagianni, CN Baxevanis and M Papamichail. (2006). Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 24:462-471.
17. Tsutsumi S, A Shimazu, K Miyazaki, H Pan, C Koike, E Yoshida, K Takagishi and Y Kato. (2001). Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Biochem Biophys Res Commun 288:413-419.
18. Ng F, S Boucher, S Koh, KS Sastry, L Chase, U Lakshmi-pathy, C Choong, Z Yang, MC Vemuri, MS Rao and V Tanavde. (2008). PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 112:295-307.
19. Le Blanc K and D Mougiakakos. (2012). Multipotent mes-enchymal stromal cells and the innate immune system. Nat Rev Immunol 12:383-396.
20. Krampera M, L Cosmi, R Angeli, A Pasini, F Liotta, A Andreini, V Santarlasci, B Mazzinghi, G Pizzolo, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386-398.
21. Krampera M. (2011). Mesenchymal stromal cell "licensing": a multistep process. Leukemia 25:1408-1414.
22. Ren G, L Zhang, X Zhao, G Xu, Y Zhang, AI Roberts, RC Zhao and Y Shi. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemo-kines and nitric oxide. Cell Stem Cell 2:141-150.
23. Augello A, R Tasso, SM Negrini, A Amateis, F Indiveri, R Cancedda and G Pennesi. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35:1482-1490.
24. Liotta F, R Angeli, L Cosmi, L Fili, C Manuelli, F Frosali, B Mazzinghi, L Maggi, A Pasini, et al. (2008). Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26:279-289.
25. Gieseke F, J Bohringer, R Bussolari, M Dominici, R Hand-gretinger and I Muller. (2010). Human multipotent mesen-chymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 116:3770-3779.
26. Selmani Z, A Naji, I Zidi, B Favier, E Gaiffe, L Obert, C Borg, P Saas, P Tiberghien, et al. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26:212-222.
27. Spaggiari GM, A Capobianco, H Abdelrazik, F Becchetti, MC Mingari and L Moretta. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cy-tokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood 111:1327-1333.
28. Chabannes D, M Hill, E Merieau, J Rossignol, R Brion, JP Soulillou, I Anegon and MC Cuturi. (2007). A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110:3691-3694.
29. Lee RH, AA Pulin, MJ Seo, DJ Kota, J Ylostalo, BL Larson, L Semprun-Prieto, P Delafontaine and DJ Prockop. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5:54-63.
30. Ren G, J Su, L Zhang, X Zhao, W Ling, A L'Huillie, J Zhang, Y Lu, AI Roberts, et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immuno-suppression. Stem Cells 27:1954-1962.
31. Bourin P, JA Peyrafitte and S Fleury-Cappellesso. (2011). A first approach for the production of human adipose tissue-derived stromal cells for therapeutic use. Methods Mol Biol 702:331-343.
32. Fekete N, M Gadelorge, D Furst, C Maurer, J Dausend, S Fleury-Cappellesso, V Mailander, R Lotfi, A Ignatius, et al. (2012). Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 14:540-554.
33. Fekete N, MT Rojewski, D Fü rst, L Kreja, A Ignatius, J Dausend and H Schrezenmeier. (2012). GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. Plos One 7:e43255.
34. Francois M, IB Copland, S Yuan, R Romieu-Mourez, EK Waller and J Galipeau. (2012). Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired inter-feron-gamma licensing. Cytotherapy 14:147-152.
35. Liu Y, L Wang, T Kikuiri, K Akiyama, C Chen, X Xu, R Yang, W Chen, S Wang and S Shi. (2011). Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat Med 17:1594-1601.
36. Tattevin P, D Monnier, O Tribut, J Dulong, N Bescher, F Mourcin, F Uhel, Y Le Tulzo and K Tarte. (2010). Enhanced indoleamine 2, 3-dioxygenase activity in patients with severe sepsis and septic shock. J Infect Dis 201:956-966.
37. Maby-El Hajjami H, P Ame-Thomas, C Pangault, O Tribut, J DeVos, R Jean, N Bescher, C Monvoisin, J Dulong, et al. (2009). Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2, 3 diox-ygenase. Cancer Res 69:3228-3237.
38. Corcione A, F Benvenuto, E Ferretti, D Giunti, V Cappiello, F Cazzanti, M Risso, F Gualandi, GL Mancardi, V Pistoia and A Uccelli. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372.
39. Traggiai E, S Volpi, F Schena, M Gattorno, F Ferlito, L Moretta and A Martini. (2008). Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 26: 562-569.
40. Francois M, R Romieu-Mourez, S Stock-Martineau, MN Boivin, JL Bramson and J Galipeau. (2009). Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 114:2632-2638.
41. Spaggiari GM, A Capobianco, S Becchetti, MC Mingari and L Moretta. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107:1484-1490.
42. Francois M, R Romieu-Mourez, M Li and J Galipeau. (2012). Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20:187-195.
43. Thomas SR, AC Terentis, H Cai, O Takikawa, A Levina, PA Lay, M Freewan and R Stocker. (2007). Post-translational regulation of human indoleamine 2, 3-dioxygenase activity by nitric oxide. J Biol Chem 282:23778-23787.
44. Najar M, G Raicevic, F Jebbawi, C De Bruyn, N Meuleman, D Bron, M Toungouz and L Lagneaux. (2012). Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett 146:50-56.
45. Abdelrazik H, GM Spaggiari, L Chiossone and L Moretta. (2011). Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T-and NK-cell proliferation and function. Eur J Immunol 41: 3281-3290.
46. Cheng P, ZQ Gao, YH Liu and YX Xue. (2009). Platelet-derived growth factor BB promotes the migration of bone marrow-derived mesenchymal stem cells towards C6 glioma and up-regulates the expression of intracellular adhesion molecule-1. Neurosci Lett 451:52-56.
47. Constantin G, S Marconi, B Rossi, S Angiari, L Calderan, E Anghileri, B Gini, SD Bach, M Martinello, et al. (2009). Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 27:2624-2635.
48. Delorme B, J Ringe, N Gallay, Y Le Vern, D Kerboeuf, C Jorgensen, P Rosset, L Sensebe, P Layrolle, T Haupl and P Charbord. (2008). Specific plasma membrane protein phe-notype of culture-amplified and native human bone marrow mesenchymal stem cells. Blood 111:2631-2635.
49. Gelbmann CM, SN Leeb, D Vogl, M Maendel, H Herfarth, J Scholmerich, W Falk and G Rogler. (2003). Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts. Gut 52:1448-1456.
50. Danese S, F Scaldaferri, S Vetrano, T Stefanelli, C Graziani, A Repici, R Ricci, G Straface, A Sgambato, et al. (2007). Critical role of the CD40 CD40-ligand pathway in regulating mu-cosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut 56:1248-1256.
51. Missiou A, D Wolf, I Platzer, S Ernst, C Walter, P Rudolf, K Zirlik, N Kostlin, FK Willecke, et al. (2010). CD40L induces inflammation and adipogenesis in adipose cells-a potential link between metabolic and cardiovascular disease. Thromb Haemost 103:788-796.
52. Landfried K, W Zhu, MC Waldhier, U Schulz, J Ammer, B Holler, D Wolff, M Edinger, K Peter, et al. (2011). Tryptophan catabolism is associated with acute GVHD after human allo-geneic stem cell transplantation and indicates activation of indoleamine 2, 3-dioxygenase. Blood 118:6971-6974.
53. Polchert D, J Sobinsky, G Douglas, M Kidd, A Moadsiri, E Reina, K Genrich, S Mehrotra, S Setty, B Smith and A Bartholomew. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38:1745-1755.
54. von Bahr L, I Batsis, G Moll, M Hagg, A Szakos, B Sundberg, M Uzunel, O Ringden and K Le Blanc. (2012). Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ec-topic tissue formation. Stem Cells 30:1575-1578.
55. Poggi A, C Prevosto, AM Massaro, S Negrini, S Urbani, I Pierri, R Saccardi, M Gobbi and MR Zocchi. (2005). Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol 175:6352-6360.
56. DelaRosa O, B Sanchez-Correa, S Morgado, C Ramirez, B del Rio, R Menta, E Lombardo, R Tarazona and JG Casado. (2012). Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev 21:1333-1343.
57. Gotherstrom C, A Lundqvist, IR Duprez, R Childs, L Berg and K le Blanc. (2011). Fetal and adult multipotent mesen-chymal stromal cells are killed by different pathways. Cy-totherapy 13:269-278.
58. Tsunematsu H, T Tatsumi, K Kohga, M Yamamoto, H Aketa, T Miyagi, A Hosui, N Hiramatsu, T Kanto, N Hayashi and T Takehara. (2012). Fibroblast growth factor-2 enhances NK sensitivity of hepatocellular carcinoma cells. Int J Cancer 130:356-364.
59. Ardolino M, A Zingoni, C Cerboni, F Cecere, A Soriani, ML Iannitto and A Santoni. (2011). DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-de-pendent activation of DNA-damage response: relevance for NK-T cell interaction. Blood 117:4778-4786.
60. Pende D, R Castriconi, P Romagnani, GM Spaggiari, S Marcenaro, A Dondero, E Lazzeri, L Lasagni, S Martini, et al. (2006). Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 107:2030-2036.
61. Bieback K, A Hecker, A Kocaomer, H Lannert, K Schallmoser, D Strunk and H Kluter. (2009). Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 27:2331-2341.
62. Oh JY, GW Roddy, H Choi, RH Lee, JH Ylostalo, RH Rosa, Jr., and DJ Prockop. (2010). Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci U S A 107:16875-16880.